Tag Archives: Novartis

Novartis v. West-Ward – Lead Compound Analysis v. Motivation to Combine

Posted on May 20, 2019 by Warren Woessner

In Novartis Pharm. v. West-Ward Pharm., Appeal no. 2018-1434 (Fed. Cir., May 12, 2019), a three judge panel of Stoll, Plager and Clevenger affirmed the district court’s ruling that the claims of Novartis’ U.S. Pat. No. 8,410,131, directed to using … Continue reading →

Posted in Obviousness | Tagged Lead Compound Analysis, Novartis, Obviousness, patent claims, POSA, prior art, West-Ward | Leave a comment

Novartis v. Breckenridge: Obviousness-Type Double Patenting Explained

Posted on December 10, 2018 by Warren Woessner

Without trying to summarize this well-written opinion by Judge Chen, I simply recommend that you store it somewhere and pull it out when you have a tricky obviousness-type double-patenting situation and want a thorough review of the doctrine. The opinion … Continue reading →

Posted in Double Patenting, Obviousness | Tagged Abbvie, Breckenridge, Double Patenting, Gilead, Novartis, Obviousness | Leave a comment

Sandoz Launches First Biosimilar Drug in U.S.

Posted on September 4, 2015 by Warren Woessner

A new chapter in the generics/innovator wars began Thursday as Sandoz, Novartis’ generics division launched its Neupogen biosimilar, Zarxio, in the U.S. at about a 15-30% discount from the price of Neupogen. While biosimilars have been marketed in Europe since 2006, Congress … Continue reading →

Posted in Biosimilars | Tagged Biosimilars, biotechnology, biotechnology law, biotechnology news, intellectual property, ip, Novartis, Patent Law, patents, Sandoz, Warren Woessner, Zarxio | Leave a comment

Novartis Wins Landmark Biosimilar Approval

Posted on March 9, 2015 by Warren Woessner

Novartis Navigates The FDA-ACA Maze – Gets Approval For Generic Neuprogen. Amgen will soon find itself in a price war with Sandoz – a Novartis company – as it tries to maintain its share of the market for Neuprogen (filgraslim). … Continue reading →